Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
NCT05253807
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG:
Pemigatinib
Sponsor
Incyte Corporation